Roche CEO Thomas Schinecker told the “Financial Times” that the company’s first anti-obesity drugs would come onto the market “much faster than expected” – possibly by 2028. This booming market is currently dominated by the American company Eli Lilly and the Danish company Novo Nordisk.
In mid-July, Roche once again published positive study data on a potential weight loss drug. This involved the candidate CT-996, which is taken once a day to treat type 2 diabetes and obesity. The drug comes from the portfolio of the American company Carmot, which Roche acquired in December for around $3 billion.
Like several anti-obesity drugs in development, CT-996 belongs to the new class of lipid-lowering drugs, the GLP-1 drugs. It achieved significant results in two sub-studies of an ongoing multi-part Phase I clinical trial. Only shortly before this, Roche had published data on its other obesity candidate CT-388, which had been positively received by analysts and investors.
Schinecker told the Financial Times that Roche could have “around seven” drugs from the Carmot acquisition, some of which are in even earlier stages of development. Roche shares have also recently benefited from the trial data.
The multi-billion dollar market for so-called GLP-1 drugs is becoming increasingly competitive. Many pharmaceutical companies, including industry giants Pfizer and Boehringer Ingelheim, are working on competing products to those of Eli Lilly and Novo Nordisk.
Adapted from German by DeepL/ac
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
This content was published on
The new regulation targets plants developed through new breeding technologies that don’t include transgenic genetic material.
WHO faces $1.8 billion budget shortfall amid US withdrawal
This content was published on
The 2026-2027 budget for the Geneva-based organisation has been reduced to $4.2 billion, on top of this year’s $600 million shortfall.
Swiss government proposes lifting nuclear power ban
This content was published on
While the centre-right and the energy sector are welcoming the Swiss government’s counter-proposal, the Greens are threatening to call a referendum.
Switzerland provisionally signs agreement on EU programmes
This content was published on
The agreement on EU programmes covers Switzerland’s involvement in initiatives like Horizon Europe, Euratom, ITER, Digital Europe, Erasmus+, and EU4Health.
Record-breaking winter for Swiss tourism driven by foreign visitors
This content was published on
A survey by Switzerland Tourism suggests this winter has outdone last season's record, largely thanks to foreign visitors and favourable weather conditions.
Swiss study predicts rise in global antibiotic use in farming
This content was published on
Global antibiotic use in livestock farming could rise by 2040, says a study by FAO and the University of Zurich. Switzerland expects minimal change.
Initiative calls for 36-week parental leave in Switzerland
This content was published on
The initiative proposes 18 weeks of non-transferable leave per parent to be taken alternately within ten years of implementation.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.